Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aminoglycoside Dosing Adjustment Based on Cmax/MIC
NCT05618457Recruiting
- Sponsor
- Hadassah Medical Organization
- Start
- Dec 2021
- Primary completion
- Dec 2025
- Modality
- Nanoparticles, Implantable Devices, Transdermal Patches
- Countries
- 1
01
Overview
Open-label, single-arm trial of gentamicin and amikacin in Gram-negative bacterial infection, sponsored by Hadassah Medical Organization. Primary endpoints: Clinical efficacy outcome, Microbiological efficacy outcome and 3 more. Started Dec 2021; status: recruiting.
02
Drugs
gentamicinamikacin
03
Conditions
Gram-negative bacterial infection
Beyond the preview
Go deeper on NCT05618457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05618457.